Why the study?
Does the Roche NT-proBNP assay improve diagnostic accuracy for structural heart disease compared to the Biomedica NT-proBNP assay in patients undergoing cardiac evaluation?
Population
180 participants prospectively recruited, including 157 consecutive patients admitted for extensive cardiac…
Comparison
Roche NT-proBNP Chemiluminescence Immunoassay vs Biomedica NT-proBNP Enzyme Immunoassay
Design
Cohort, Classification of heart failure stage was done by one experienced…
Authors
Loading...
Roche assay may aid stage B HF detection over Biomedica; hypothesis-generating and should not yet change practice.
Does the Roche NT-proBNP assay improve diagnostic accuracy for structural heart disease compared to the Biomedica NT-proBNP assay in patients undergoing cardiac evaluation?
The Roche noncompetitive NT-proBNP assay demonstrates superior diagnostic accuracy for detecting asymptomatic structural heart disease compared to the Biomedica competitive assay.
Mueller et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: